Loading stock data…
GRI
$2.18+0.00 (+0.00%)
Market ClosedLast close May 1
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GRI Bio, Inc. in the Healthcare sector is trading at $2.18. The stock is currently near its 52-week low of $2.10, remaining 92.1% below its 200-day moving average. Technical signals show neutral RSI of 37 and bearish MACD signal, explaining why GRI maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 37) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.18
Potential Upside
5%
Whystock Fair Value$2.29
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$160.00+7239.4%
Range$40.00 – $280.00
Fundamentals
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.48M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-199.00%
Volume
Today's trading volume
24,634
Recent News
How The Grainger (LSE:GRI) Investment Story Is Evolving As The Narrative Holds Steady
Analysts have kept their price targets for Grainger unchanged, indicating that the formal outlook on the stock has not shifted in this latest update. While there is no new analyst commentary accompanying this stance, the absence of changes can still indicate how expectations are holding steady. Ahead, you will see how to track these updates and fit them into your own view of Grainger as the narrative continues to evolve. Stay updated as the Fair Value for Grainger shifts by adding it to your...
3 Undervalued Small Caps In Global With Recent Insider Activity
In a week marked by geopolitical tensions and fluctuating energy prices, global markets experienced mixed results, with small-cap indices like the S&P MidCap 400 and Russell 2000 showing resilience by ending their losing streaks. Amidst these volatile conditions, investors are increasingly attentive to small-cap stocks that exhibit strong fundamentals and recent insider activity, as these factors can indicate potential value opportunities in an uncertain economic landscape.
Sector Update: Health Care Stocks Climb Late Afternoon
Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index up 1.8% and the Hea
Sector Update: Health Care Stocks Higher Thursday Afternoon
Health care stocks rose Thursday afternoon, with the NYSE Health Care Index up 1.4% and the Health C
GRI Bio reports six-week interim safety outcomes from trial of GRI-0621 for IPF
The trial was recommended by the interim analysis committee to proceed as per the plan.